Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Sharing that message on a wider scale with the Novo Nordisk team "means the world to me", Brand added. And while he admitted ...

Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

A medical expert warned of the side effects of the newly launched weight loss drug and advised that the drug should be taken ...

The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Investigation ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently updated its clinical study titled ...

Emma Kleck has been totally dependent on insulin, the lifesaving medication for people living with diabetes, for 25 years.